ReviewInternational journal of molecular sciences2022
In Vivo Applications of Molecularly Imprinted Polymers for Drug Delivery: A Pharmaceutical Perspective.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Molecularly Imprinted Polymer (MIP)-Based Electrochemical Sensors for Pharmaceutical Detection in Wastewater: Imprinting Strategies, Analytical Performance, and Challenges.Sensors (Basel, Switzerland) · 2026Review
- Engineering molecularly imprinted polymers for receptor-specific cancer therapeutics.Nanoscale · 2026Review
- Magnetic molecularly imprinted polymer coated with chitosan shell for enhanced controlled drug release.Scientific reports · 2026Article
- Crossing the Blood-Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Advancing Drug Delivery with Biodegradable Molecularly Imprinted Polymers: From Design to Clinical Prospects.Drug design, development and therapy · 2026Review
- Review
- Progress in Molecular Imprinting-From Inhibition of Enzymatic Activity to Regulation of Cellular Pathways.Medicinal research reviews · 2025Review
- Recognition-induced destabilization: controlled release from molecularly imprinted chitosan nanoparticlesRSC advances · 2025Article
- Review
- Advances in molecularly imprinted polymers for clinical biomarker detection (2021-2025).Mikrochimica acta · 2025Review
- Review
- Molecularly Imprinted Polymer Advanced Hydrogels as Tools for Gastrointestinal Diagnostics.Gels (Basel, Switzerland) · 2025Review
- Molecularly Imprinted Polymeric Nanoparticles as Drug Delivery System for Tenofovir, an Acyclic Nucleoside Phosphonate Antiviral.Pharmaceutics · 2024Article
- Unlocking New Avenues: Solid-State Synthesis of Molecularly Imprinted Polymers.International journal of molecular sciences · 2024Article
- Targeted Clindamycin Delivery Systems: Promising Options for Preventing and Treating Bacterial Infections Using Biomaterials.International journal of molecular sciences · 2024Review
- Chloramphenicol-imprinted polychitosan bounded with carbon dots as fluorescent sensor, dispersive sorbent, and drug carrier.Mikrochimica acta · 2024Article
- Recent Advances in Molecularly Imprinted Polymers and Their Disease-Related Applications.Polymers · 2023Review
- Molecularly Imprinted Carriers for Diagnostics and Therapy-A Critical Appraisal.Pharmaceutics · 2023Review
- Biodegradable and Sustainable Synthetic Antibodies-A Perspective.Pharmaceutics · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Molecularly imprinted polymers (MIPs) have been proven to be a promising candidate for drug delivery systems (DDS) due to their ability to provide a sustained and controlled drug release, making them useful for treating a wide range of medical conditions. MIP-based DDS offer many advantages, including the administration of a smaller drug doses, due to the higher drug payload or targeted delivery, resulting in fewer side effects, as well as the possibility of attaining high concentrations of the drug in the targeted tissues. Whether designed as drug reservoirs or targeted DDS, MIPs are of great value to drug delivery as conventional drug formulations can be redesigned as DDS to overcome the active pharmaceutical ingredient's (APIs) poor bioavailability, toxic effects, or other shortcomings that previously made them less efficient or unsuitable for therapy. Therefore, MIP design could be a promising alternative to the challenging research and development of new lead compounds. Research on MIPs is primarily conducted from a material science perspective, which often overlooks some of their key pharmaceutical requirements. In this review, we emphasize the specific features that make MIPs suitable for clinical use, from both a material science and a biopharmaceutical perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.